Read by QxMD icon Read


Gema Bruixola, Javier Caballero, Federica Papaccio, Angelica Petrillo, Aina Iranzo, Miguel Civera, Miriam Moriana, Neus Bosch, Maria Maroñas, Ines González, Miguel Pastor, Andrés Cervantes
Background: Locally advanced head and neck squamous cell carcinoma (LAHNSCC) is a heterogeneous disease in which better predictive and prognostic factors are needed. Apart from TNM stage, both systemic inflammation and poor nutritional status have a negative impact on survival. Methods: We retrospectively analysed two independent cohorts of a total of 145 patients with LAHNSCC treated with induction chemotherapy followed by concurrent chemoradiotherapy at two different academic institutions...
2018: ESMO Open
Paolo Bossi
No abstract text is available yet for this article.
2018: ESMO Open
Saori Mishima, Akihito Kawazoe, Hiroshi Matsumoto, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino, Elizabeth M Nonte, Sudhakar Chintharlapalli, Aejaz Nasir, Takeshi Kuwata, Kohei Shitara
Background: Ramucirumab (RAM), a monoclonal antibody for vascular endothelial growth factor 2 (VEGFR2), has been effective for advanced gastric adenocarcinoma (AC). However, little is known about the efficacy of RAM-containing chemotherapy (RAM-CTx) in gastric neuroendocrine carcinoma (G-NEC). Methods: We retrospectively analysed and compared the clinical outcomes of patients (pts) with G-NEC receiving RAM-CTx, G-NEC receiving CTx without RAM and AC receiving RAM-CTx in our hospital...
2018: ESMO Open
(no author information available yet)
[This corrects the article DOI: 10.1136/esmoopen-2018-000420.].
2018: ESMO Open
Peter Schmid
No abstract text is available yet for this article.
2018: ESMO Open
Desamparados Roda, Valentina Gambardella, Andrés Cervantes
No abstract text is available yet for this article.
2018: ESMO Open
Jordi Remon, Rodrigo Dienstmann
Precision oncology based on next-generation sequencing (NGS) test is growing in daily clinical practice. However, the real impact of this strategy in patients' outcome on a large scale remains uncertain. In this review, we summarise existing literature on this topic, limitations for broad NGS implementation, bottlenecks in genomic variant interpretation and the role of molecular tumour boards.
2018: ESMO Open
Christian Maurer, Lorraine Tulpin, Michel Moreau, Cristina Dumitrescu, Evandro de Azambuja, Marianne Paesmans, Jean-Marie Nogaret, Martine J Piccart, Ahmad Awada
Background: Patients with metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC) frequently experience brain metastases (BM). We aimed to define risk factors for the development of BM in patients with HER2+ BC and to report on their outcome. Methods: This is a retrospective analysis of patients diagnosed with HER2+ BC between January 2000 and December 2014 at Institut Jules Bordet, Belgium. Statistical analyses were conducted with SAS V...
2018: ESMO Open
Tetsuya Kusumoto, Megumi Ishiguro, Eiji Nakatani, Motoki Yoshida, Tsukasa Inoue, Yoshihiko Nakamoto, Akio Shiomi, Akinori Takagane, Eiji Sunami, Hiroharu Shinozaki, Yasumasa Takii, Atsuyuki Maeda, Hitoshi Ojima, Hiroki Hashida, Mitsuhiro Mukaiya, Tadashi Yokoyama, Masato Nakamura, Yoshinori Munemoto, Kenichi Sugihara
Objective: Adjuvant Chemotherapy Trial of TS-1 for Colon Cancer (ACTS-CC), a randomised phase III trial, demonstrated that adjuvant therapy with S-1 for stage III colon cancer was non-inferior in 3-year disease-free survival (DFS) to that of tegafur-uracil plus leucovorin (UFT/LV). We updated DFS and overall survival (OS) and performed T x N subset analysis. Methods: A total of 1518 patients with curatively resected stage III colon cancer were randomly assigned to receive S-1 (80-120  mg/day on days 1-28 every 42 days, four courses) or UFT/LV (UFT: 300-600  mg/day and LV: 75  mg/day on days 1-28 every 35 days, five courses)...
2018: ESMO Open
Maria Vittoria Dieci, Francesco Massari, Raffaele Giusti, Alessandro Inno, Giuseppe Lombardi, Laura Noto, Antonio Passaro, Filippo Pietrantonio, Francesca Spada, Monica Valente, Massimo Di Maio, Valter Torri
Background: The professional gender gap is increasingly recognised in oncology. We explored gender issues perception and gender influence on professional satisfaction/gratification among young Italian oncologists. Methods: Italian oncologists aged ≤40 years and members of the Italian Association of Medical Oncology were invited to participate in an online survey addressing workload/burnout, satisfaction in professional abilities and relations, relevant factors for professional gratification, and gender barriers...
2018: ESMO Open
Marina Parry
No abstract text is available yet for this article.
2018: ESMO Open
Jan Norum, Carsten Nieder
Background: Programmed death ligand 1 (PD-L1) targeting immunotherapies, as pembrolizumab and nivolumab, have significantly improved outcome in patients with non-small cell lung cancer (NSCLC). Tobacco smoking is the number one risk factor for lung cancer and is linked to 80%-90% of these cancers. Smoking during cancer therapy may influence on radiotherapy and chemotherapy outcome. We aimed to review the knowledge in immunotherapy. Patients and methods: A systematic review was done...
2018: ESMO Open
Chiara Tarantelli, Elena Bernasconi, Eugenio Gaudio, Luciano Cascione, Valentina Restelli, Alberto Jesus Arribas, Filippo Spriano, Andrea Rinaldi, Afua Adjeiwaa Mensah, Ivo Kwee, Maurilio Ponzoni, Emanuele Zucca, Laura Carrassa, Maria E Riveiro, Keyvan Rezai, Anastasios Stathis, Esteban Cvitkovic, Francesco Bertoni
Background: The outcome of patients affected by mantle cell lymphoma (MCL) has improved in recent years, but there is still a need for novel treatment strategies for these patients. Human cancers, including MCL, present recurrent alterations in genes that encode transcription machinery proteins and of proteins involved in regulating chromatin structure, providing the rationale to pharmacologically target epigenetic proteins. The Bromodomain and Extra Terminal domain (BET) family proteins act as transcriptional regulators of key signalling pathways including those sustaining cell viability...
2018: ESMO Open
Susana Banerjee, Urania Dafni, Tamara Allen, Dirk Arnold, Giuseppe Curigliano, Elena Garralda, Marina Chiara Garassino, John Haanen, Eva Hofstädter-Thalmann, Caroline Robert, Cristiana Sessa, Zoi Tsourti, Panagiota Zygoura, Solange Peters
Background: Although women account for a growing proportion of the oncology workforce, there is evidence they are under-represented in leadership roles. To gain further insights into this issue and extend understanding of gender challenges, the European Society for Medical Oncology Women for Oncology (W4O) Committee undertook a survey of female and male oncologists in 2016. Design: The 2016 W4O questionnaire included questions on (1) Demographics and professional environment, (2) Gender impact on career development, (3) Challenges for career progression and inappropriate behaviour experienced in the workplace, (4) Barriers for gender parity and (5) The gender gap...
2018: ESMO Open
Eva Hofstädter-Thalmann, Urania Dafni, Tamara Allen, Dirk Arnold, Susana Banerjee, Giuseppe Curigliano, Elena Garralda, Marina Chiara Garassino, John Haanen, Caroline Robert, Cristiana Sessa, Zoi Tsourti, Panagiota Zygoura, Solange Peters
Background: While the global workforce is approaching gender parity, women occupy a small number of management level positions across most professions, including healthcare. Although the inclusion of women into the membership of many oncology societies has increased, the under-representation of women in leadership roles within international and national oncology societies remains relatively consistent. Moreover, the exact status of women participating as board members or presidents of oncology societies or as speakers at oncology congresses was undocumented to date...
2018: ESMO Open
Elena Wolff-Holz, Juan Garcia Burgos, Rosa Giuliani, Gustaf Befrits, Johan de Munter, Luisa Avedano, Murray Aitken, Rosa Gonzalez-Quevedo, Malvika Vyas, Elisabeth G E de Vries, Josep Tabernero
With the imminent arrival of oncology biosimilars in the therapeutic paradigm, stakeholders including a clinician, specialist nurse, patient advocate, regulator and economist provide their perspective on optimising the uptake of these new agents in the treatment of cancer. A number of key messages emerge, based on the discussion that took place during a session of the European Society for Medical Oncology's Annual Congress, ESMO Madrid 2017. First, for successful integration of biosimilars into the global healthcare paradigm, informing and educating the full scope of stakeholders, including clinicians, nurses, pharmacists and patients, is primordial...
2018: ESMO Open
Florian Cabillic, Paul Hofman, Marius Ilie, Nir Peled, Maximilian Hochmair, Manfred Dietel, Maximilian Von Laffert, John R Gosney, Fernando Lopez-Rios, Gilles Erb, Uwe Schalles, Fabrice Barlesi
Introduction: Lung cancer is the most common cancer worldwide. Latest guidelines from the College of American Pathologist and the European society of medical oncologists indicate anaplastic lymphoma kinase (ALK) rearrangement testing is standard practice. Historically, diagnostics for ALK used fluorescence in situ hybridisation (FISH); however, immunohistochemical (IHC) assays are becoming common practice. Unfortunately, recent assessment of current practice indicated that not all patients who should be tested for ALK translocation are undergoing ALK testing...
2018: ESMO Open
Wolfgang Wagner
No abstract text is available yet for this article.
2018: ESMO Open
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"